Xanomeline, an M1/M4 preferring muscarinic cholinergic receptor agonist, produces antipsychotic-like activity in rats and mice

Schizophrenia Research

Volumn 42, Issue 3, 2000, Pages 249-259

  Shannon, Harlan E ^a   Rasmussen, Kurt ^a   Bymaster, Frank P ^a   Hart, John C ^a   Peters, Steven C ^a   Swedberg, Michael D B ^b   Jeppesen, Lone ^b   Sheardown, Malcolm J ^b   Sauerberg, Per ^b   Fink Jensen, Anders ^b  

^a ELI LILLY AND COMPANY   (United States)

^b NOVO NORDISK A S   (Denmark)

Author keywords

Antipsychotic like activity; Behavior; Electrophysiology; Microdialysis; Schizophrenia; Xanomeline

Indexed keywords

2,3,4,5 TETRAHYDRO 7,8 DIHYDROXY 1 PHENYL 1H 3 BENZAZEPINE; APOMORPHINE; CLOZAPINE; HALOPERIDOL; MUSCARINIC RECEPTOR BLOCKING AGENT; OLANZAPINE; QUINPIROLE; SCOPOLAMINE; XANOMELINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; AVOIDANCE BEHAVIOR; BEHAVIOR; CATALEPSY; CLIMBING; CONTROLLED STUDY; DOPAMINE RELEASE; DOPAMINERGIC NERVE CELL; DRUG EFFECT; ELECTROPHYSIOLOGY; EXTRAPYRAMIDAL SYMPTOM; HALLUCINATION; MALE; MICRODIALYSIS; NONHUMAN; PREFRONTAL CORTEX; PRIORITY JOURNAL; RAT; SCHIZOPHRENIA;

ALZHEIMER DISEASE; ANIMALS; ANTIPSYCHOTIC AGENTS; BRAIN; CHOLINERGIC AGONISTS; CONDITIONING (PSYCHOLOGY); DISEASE MODELS, ANIMAL; DOPAMINE; ELECTROPHYSIOLOGY; MALE; MICE; MICE, INBRED STRAINS; MUSCARINIC AGONISTS; NEURONS; PSYCHOTIC DISORDERS; PYRIDINES; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, CHOLINERGIC; SCHIZOPHRENIA; THIADIAZOLES;

EID: 0034607566     PISSN: 09209964     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0920-9964(99)00138-3     Document Type: Article

References (40)

1. Arnt J. Pharmacological specificity of conditioned avoidance response inhibition in rats: inhibition by neuroleptics and correlation to dopamine receptor blockade. Acta Pharmacol. Toxicol. 51:1982;321-329.
2. Arnt J., Hyttel J. Inhibition of SKF 38393- and pergolide-induced circling in rats with unilateral 6-OHDA lesion is correlated to dopamine D-1 and D-2 receptors affinities in vitro. J. Neural Trans. 67:1986;225-240.
3. Bernard V., Normand E., Block B. Phenotypical characterization of the rat striatal neurons expressing muscarinic receptor genes. J. Neurosci. 12:1992;3591-3600.
4. Bodick N.C., Offen W.W., Levey A.I., Cutler N.R., Gauthier S.G., Satlin A., Shannon H.E., Tollefson G.D., Hurley D.J., Paul S.M. The effects of xanomeline, an M1-selective muscarinic agonist, on cognitive function and behavioral symptoms in Alzheimer's disease. Arch. Neurol. 54:1997;465-473.
5. Bunney B.S., Grace A.A. Acute and chronic haloperidol treatment: comparison of effects on nigral dopaminergic cell activity. Life Sci. 23:1978;1715-1728.
6. Bymaster F.P., Shannon H.E., Rasmussen K.N.W., DeLapp N.W., Mitch C.H., Ward J.S., Calligaro D.O., Ludvigsen T.S., Sheardown M.J., Olesen P.H., Swedberg M.D.B., Sauerberg P., Fink-Jensen A. Unexpected antipsychotic-like activity with the muscarinic receptor ligand (5R,6R)6-(3-propylthio-1,2,5-thiadiazol-4-yl)-1-azabicyclo[3.2.1]octane. Eur. J. Pharmacol. 356:1998;109-119.
7. Bymaster F.P., Whitesitt C.A., Shannon H.E., DeLapp N.W., Ward J.S., Calligaro D.O., Shipley L.A., Buelke-Sam J.L., Bodick N.C., Farde L., Sheardown M.J., Olesen P.H., Hansen K.T., Suzdak P.D., Swedberg M.D.B., Sauerberg P., Mitch C.H. Xanomeline: a selective muscarinic agonist for the treatment of Alzheimer's disease. Drug Dev. Res. 40:1997;158-170.
8. 1 muscarinic agonist xanomeline (LY246708/NNC11-0232). J. Pharmacol. Exp. Ther. 269:1994;282-289.
9. Chiodo L.A., Bunney B.S. Typical and atypical neuroleptics: differential effects of chronic administration on the activity of A9 and A10 opaminergic neurons. J. Neurosci. 3:1983;1609-1619.
10. Costall B., Eniojukan J.F., Naylor R.J. The mesolimbic nucleus accumbens is critically involved with the mediation of the motor inhibitory and facilitatory effects of dopamine agonists on mouse spontaneous climbing behaviour. Eur. J. Pharmacol. 96:1983;201-210.
11. Costall B., Fortune D.H., Naylor R.J., Nohria V. The mesolimbic system, denervation and the climbing response in the mouse. Eur. J. Pharmacol. 66:1980;207-215.
12. Costall B., Naylor R.J., Nohria V. Climbing behavior induced by apomorphine in mice: a potential model for the detection of neuroleptic activity. Eur. J. Pharmacol. 50:1978;39-50.
13. Cummings J.L., Gorman D.G., Shapira J. Physostigmine ameliorates the delusions of Alzheimer's disease. Biol. Psychiatry. 33:1993;536-541.
14. Davis K.L., Berger P.A. Pharmacological investigations of the cholinergic imbalance hypotheses of movement disorders and psychosis. Biol. Psychiatry. 13:1978;23-49.
15. DeLapp N., Eckols K., Shannon H.E. Muscarinic agonist inhibition of rat striatal adenylate cyclase is enhanced by dopamine stimulation. Life Sci. 59:1996;565-572.
16. Deutch A.Y. The regulation of subcortical dopamine systems by the prefrontal cortex: interactions of central dopamine systems and the pathogenesis of schizophrenia. J. Neural. Transm. 36:(Suppl.):1992;61-89.
17. Devanand D.P., Marker K., Michales K.S., Sackeim H.A., Bell K., Sullivan M.A., Cooper T.B., Pelton G.H., Mayeux R. A randomized, placebo-controlled dose-comparison trial of haloperidol for psychosis and disruptive behaviors in Alzheimer's disease. Am. J. Psychiatry. 155:1998;1512-1520.
18. Fink-Jensen A., Kristensen P., Shannon H.E., Calligaro D.O., DeLapp N.W., Whitesitt C., Ward J.S., Thomsen C., Rasmussen T., Sheardown M.J., Jeppesen L., Sauerberg P., Bymaster F.P. Muscarinic agonists exhibit functional dopamine antagonism in unilaterally 6-OHDA lesioned rats. Neuroreport. 9:1998;3481-3486.
19. Gao A.G., Cui W.Y., Liu C.G. Modulation of apomorphine-induced rotations in unilaterally 6-hydroxydopamine lesioned rats by cholinergic agonists and antagonists. Life Sci. 60:1997;317-323.
20. Goldstein J.M., Litwin C.L., Sutton E.B., Malick J.B. Seroquel: electrophysiological profile of a potential atypical antipsychotic. Psychopharmacology. 112:1993;673-680.
21. Gorman D.G., Read S., Cummings J.L. Cholinergic therapy of behavioral disturbances in Alzheimer's disease. Behav. Neurol. Neuropsychiat. Neuropsychol. 6:1993;229-234.
22. Gronier B., Rasmussen K. Activation of midbrain presumed dopaminergic neurones by muscarinic cholinergic receptors: an in vivo electrophysiological study in the rat. Br. J. Pharmacol. 124:1998;455-464.
23. Kaufer D.I., Cummings J.L., Christine D. Effect of tacrine on behavioral symptoms in Alzheimer's disease: an open label study. J. Geriatr. Psychiatry Neurol. 9:1996;1-6.
24. Li X.M., Perry K.W., Wong D.T., Bymaster F.P. Olanzapine increases in vivo dopamine and norepinephrine release in rat prefrontal cortex, nucleus accumbens and striatum. Psychopharmacology. 136:1998;153-161.
25. 3H]dopamine release from dendrosomes of rat substantia nigra. Nannyn Schmiedeberg's Arch. Pharmacol. 344, 275-280.
26. Moghaddam B., Bunney B.S. Utilization of microdialysis for assessing the release of mesotelencephalic dopamine following clozapine and other antipsychotic drugs. Prog. Neuro-Psychopharmacol. Biol. Psychiatry. 14:1990;S51-S57.
27. Moore N.A., Tye N.C., Axton M.S., Risius F.C. The behavioral pharmacology of olanzapine, a novel 'atypical' antipsychotic agent. J. Pharmacol. Exp. Ther. 262:1992;545-551.
28. Morelli M., Fenu S., Cozzolino A., Pinna A., Carta A., Di Chiara G. Blockade of muscarinic receptors potentiates D1 dependent turning behavior and c-fos expression in 6-hydroxydopamine-lesioned rats but does not influence D2 mediated responses. Neuroscience. 53:1993;673-678.
29. Olianas M.C., Onali P. Antagonism of striatal muscarinic receptors inhibiting dopamine D1 receptor-stimulated adenylyl cyclase activity by cholinoceptor antagonists used to treat Parkinson's disease. Br. J. Pharmacol. 118:1996;827-828.
30. Olianas M.C., Onali P., Neff N.H., Costa E. Muscarinic receptors modulate dopamine-activated adenylate cyclase of rat striatum. J. Neurochem. 41:1983;1364-1369.
31. Pehek E.A., Yamamoto B.K. Differential effects of locally administered clozapine and haloperidol on dopamine efflux in the rat prefrontal cortex and caudate-putamen. J. Neurochem. 63:1994;2118-2124.
32. Perry K.W., Bymaster F.P., Shannon H.E., Rasmussen K., DeLapp N.W., Zhang W., Ward J.S., Calligaro D.O., Fink-Jensen A., Sheardown M., Jeppesen L., Sauerberg P. The muscarinic agonist xanomeline has antipsychotic-like activity in animals and in man. Schizophr. Res. 36:1999;117-118.
33. Schneider L.S., Pollock V.E., Lyness S.A. A meta-analysis of controlled trials of neuroleptic treatment of dementia. J. Am. Geriatr. Soc. 38:1990;553-563.
34. 1 muscarinic receptor agonist. J. Pharmacol. Exp. Ther. 269:1994;271-281.
35. Shannon H.E., Hart J.C., Bymaster F.P., Calligaro D.O., DeLapp N.W., Mitch C.H., Ward J.S., Fink-Jensen A., Sauerberg P., Jeppesen L., Sheardown M.J., Swedberg M.D.B. Muscarinic receptor agonists, like dopamine receptor antagonist antipsychotics, inhibit conditioned avoidance responding in the rat. J. Pharmacol. Exp. Ther. 290:1999;901-907.
36. Stockton M.E., Rasmussen K. Electrophysiological effects of olanzapine, a novel atypical antipsychotic, on A9 and A10 dopamine neurons. Neuropsychopharmacology. 14:1996;97-104.
37. Verhave T., Owen J.E., Slater O.H. Effects of various drugs on escape and avoidance behavior. Prog. Neurobiol. 3:1958;267-301.
38. White F.J., Wang R.Y. Differential effects of classical and atypical antipsychotic drugs on A9 and A10 dopamine neurons. Science. 221:1983;1054-1057.
39. White K.E., Cummings J.L. Schizophrenia and Alzheimer's disease: clinical and pathophysiologic analogies. Comp. Psychiatry. 37:1996;188-195.
40. Winn P. Schizophrenia research moves to the prefrontal cortex. Trends Neurol. Sci. 17:1994;265-268.